Sheep cull follows staff cuts at PPL

Related tags Cloning Bayer

Scotland's PPL has started a mass slaughter of its flock of sheep
engineered to produce alpha-1 antitrypsin in their milk. The cull
could spell the end of the firm's ambitions in transgenic
production.

Scotland's PPL has started a mass slaughter of its transgenic sheep engineered to produce alpha-1 antitrypsin, a drug intended for emphysema, in their milk.

The decision to dramatically reduce the number of sheep in the 6,500-strong flock comes in the wake of PPL's partner Bayer deciding to suspend the collaboration and focus on other development projects.

PPL is best known for its historic cloning of Dolly the sheep, the first animal to be cloned from an adult mammalian cell but which died prematurely earlier this year. The Bayer partnership focusing on recombinant AAT was its most advanced project, and the demise of the project last month led to a dramatic effort to cut costs at the Scottish firm, with 140 staff at its Roslin facility told that they were likely to lose their jobs.

The cull on PPL's farms on East Lothian and New Zealand started yesterday, although PPL has said it will retain a "significant" number of animals in case the project should ever restart.

Bayer said last month that it may be able to revisit the project in three years' time. However, the cost of maintaining the flock is high, as the animals require close monitoring to ensure their health, and analysts have suggested that the latest move could signal the end of PPL's transgenic production technology.

PPL is considering a liquidation of the company's assets, selling the firm or continuing to operate in a reduced state with a focus on developing another protein, fibrin I, as a tissue sealant to stop bleeding during surgery.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars